Akari Therapeutics Has Selected The Version Of Long-Acting PAS-Nomacopan That It Plans To Advance Into Clinical Trials; It Remains On Track For An IND Submission In 1H Of 2024 And The Start Of Clinical Trials In 2H Of 2024
Portfolio Pulse from Benzinga Newsdesk
Akari Therapeutics has chosen the version of long-acting PAS-Nomacopan that it will advance into clinical trials. The company is on schedule for an IND submission in the first half of 2024 and the start of clinical trials in the second half of 2024.
July 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akari Therapeutics' decision to advance a version of PAS-Nomacopan into clinical trials could potentially impact the company's stock. The IND submission and start of trials are expected in 2024.
The decision to advance PAS-Nomacopan into clinical trials is a significant step for Akari Therapeutics. This could potentially attract investor interest and positively impact the company's stock. However, the actual impact will depend on the success of the trials and market conditions at the time.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100